Related Experiment Videos
Sentinel lymph node dissection for primary cutaneous melanoma: a community hospital's initial experience
F A Habib1, M E Lodish, V K Mittal
1Department of General Surgery, Providence Hospital & Medical Centers, Southfield, Michigan 48075, USA.
The American Surgeon
|April 12, 2000
Summary
Sentinel lymph node dissection (SLND) accurately identifies occult metastases in melanoma patients. This community hospital study shows SLND is effective and safe, comparable to academic centers, offering a viable option for intermediate-thickness cutaneous melanoma.
Area of Science:
- Oncology
- Surgical Oncology
- Dermatology
Background:
- Regional lymph node management is controversial in intermediate-thickness cutaneous melanoma.
- Elective lymph node dissection has not shown survival benefits.
- Sentinel lymph node dissection (SLND) aims to identify occult metastases for targeted treatment.
Purpose of the Study:
- To evaluate the initial experience and feasibility of SLND in a community hospital setting.
- To assess the accuracy and safety of SLND for intermediate-thickness cutaneous melanoma.
- To compare community hospital outcomes with those from academic centers.
Main Methods:
- Fifteen patients with intermediate-thickness melanoma underwent preoperative lymphoscintigraphy and intraoperative lymphatic mapping with isosulfan blue.
- Dissection was guided by a hand-held gamma probe measuring radioactivity.
- Sentinel nodes were evaluated using hematoxylin and eosin staining and immunohistochemistry (S-100, HMB-45).
Main Results:
- Sentinel nodes were identified in 100% of patients (15/15).
- Successful resection of sentinel nodes was achieved in all patients.
- No occult micrometastases were found, and all patients remained disease-free at a mean follow-up of 221 days.
Conclusions:
- SLND is a feasible and accurate technique for community hospitals treating cutaneous melanoma.
- Outcomes in this community setting compare favorably with academic institutions.
- SLND provides a valuable option for staging melanoma patients in non-academic settings.